Indonesian Pharma Firm OBAT Eyes Growth with New Plant, Govt Nutrition Program
JAKARTA, investortrust.id—PT Brigit Biofarmaka Teknologi Tbk, a pharmaceutical company backed by prominent businessman Dahlan Iskan, announced plans Thursday to build a new production facility in Sukoharjo, Central Java, aimed at manufacturing tablets and soft gel dietary supplements by 2026.
The move follows its recent debut on the Indonesia Stock Exchange (IDX), where it raised Rp 59.5 billion ($3.8 million) through an initial public offering (IPO). The company was traded under ticker OBAT.
OBAT President Director Is Heriyanto said a portion of the IPO proceeds will fund raw material purchases, working capital, and marketing expansion, while profits will be directed toward constructing the new plant.
“We’ll run parallel operations—using IPO funds for materials and our earnings for the factory,” Heriyanto told investortrust.id during an interview in Jakarta. The company also plans to establish an office-laboratory complex to support R&D and production scaling.
OBAT, which reported a 2024 net profit of Rp 30 billion ($1.9 million), targets 20% net profit growth in 2025. Heriyanto cited digital marketing investments and participation in the government’s Free Nutritious Meal (MBG) program as key drivers. The MBG initiative, which includes OBAT’s spirulina milk and neoalgae spirulina products in its menus, is expected to bolster sales.
“We’ve structured a roadmap to address priorities incrementally,” Heriyanto added, noting that the firm will balance expansion with ongoing operational demands.
OBAT Stock Chart